Esperion Launches New Scientific Website
February 24 2023 - 1:40PM
With a focus on science and clinical evidence, Esperion today
announced the launch of the website, esperionscience.com. This
website, geared towards the scientific and medical communities,
delivers information about Esperion’s CLEAR program and the
clinical trials comprising the CLEAR program, the Company’s
pipeline, and information about cardiometabolic disease.
“I am thrilled to invite scientific and medical colleagues
tackling cardiovascular and cardiometabolic disease and interested
in our science to esperionscience.com,” said JoAnne Foody, MD,
FACC, FAHA, chief medical officer for Esperion. “Science is at the
core of everything we do at Esperion. We are proud of our
commitment to advance the science of lipid lowering in diverse and
broad populations not addressed in current trials, culminating in
our CLEAR Outcomes trial. We look forward to expanding our
scientific knowledge to novel populations and addressing unmet need
through our pipeline platforms. esperionscience.com will
showcase our current and emerging science and our dedication to
ensuring that the millions of patients with or at risk for
cardiovascular disease achieve lower LDL-C goals sooner.”
Visitors to the website can review all the clinical trials that
Esperion has conducted with abstracts, publications, and links to
clinicaltrials.gov. New trials and pipeline updates will be posted
when available. Also included are videos featuring prominent
clinicians and scientists highlighting the burgeoning national
issue of cardiovascular and cardiometabolic disease, the mechanism
of action of our lipid lowering compounds, and key aspects of the
CLEAR program. “This repository will serve as an easy to navigate
resource for health care providers searching for information or
connections to Esperion’s science,” stated Michelle Gearhart,
PharmD, director of scientific affairs at Esperion.
Visit esperionscience.com.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024